Company news

Alvotech news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

November 3, 2025

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

November 1, 2025

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

November 1, 2025

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

October 21, 2025

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

October 5, 2025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

October 5, 2025

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

September 21, 2025

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

September 21, 2025

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

September 18, 2025

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

September 3, 2025

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

August 20, 2025

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

August 19, 2025

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

August 12, 2025

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

August 12, 2025

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8: 00 am EDT

August 5, 2025

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

July 9, 2025

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

July 8, 2025

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

July 8, 2025

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

July 2, 2025

Granting of Stock Options and Vesting of Restricted Share Units

June 30, 2025

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

June 30, 2025

Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility

June 25, 2025

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

June 24, 2025

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

June 24, 2025

Main Results of 2025 Annual and Extraordinary General Meeting

June 24, 2025

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

June 22, 2025

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

June 22, 2025

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

June 10, 2025

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

June 10, 2025

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

June 5, 2025

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

June 5, 2025

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

June 4, 2025

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

June 3, 2025

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

June 3, 2025

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

June 3, 2025

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

June 1, 2025

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

May 27, 2025

Alvotech Annual General Meeting to be held June 25, 2025

May 25, 2025

Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today

May 18, 2025

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

May 18, 2025

Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm

May 15, 2025

Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

May 8, 2025

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

May 7, 2025

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025

May 6, 2025

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 6, 2025

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 6, 2025

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

May 4, 2025

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8: 00 am EDT

May 1, 2025

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8: 00 am EDT (14: 00 CET)

May 1, 2025

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

March 26, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.